mOm Incubators wins FDA nod for first-of-its-kind portable incubator
January 21, 2026
mOm Incubators announced today that the FDA granted 510(k) clearance for its Essential Incubator system.
mOm Incubators announced today that the FDA granted 510(k) clearance for its Essential Incubator system.
A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most powerful genetic “on switches” in cancer cells, called super-enhancers, drive unusually intense gene activity. That high gear creates stress on the DNA and can cause dangerous breaks.
A multidisciplinary team has developed a selective compound that inhibits an enzyme tied to inflammation in people at genetic risk for Alzheimer’s, while preserving normal brain function and crossing the blood-brain barrier.
What’s the first thing you did when you woke up this morning? Maybe you swung your legs over the side of your bed, placed your feet on the floor and stood up. Simple, right?
A team of Canadian scientists has uncovered a new way to slow the growth of glioblastoma, the most aggressive and currently incurable form of brain cancer—and identified an existing medication that could treat it.
Researchers from the Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC) have developed a series of light-activatable drug candidates that could serve as a potential treatment for psoriasis.
The project began at the University of Pittsburgh’s Makerspace during the Pitt Challenge Healthcare Hackathon in 2021 and has since grown into a community driven effort.
Researchers have identified a metabolically sensitive cell subtype in the eye’s drainage system which shows early signs of dysfunction in a genetic mouse model of glaucoma.
MORGANTOWN, W.Va., Jan. 20, 2026 /PRNewswire/ — Omnia Medical, a medical technology company developing surgical solutions for spine and interventional pain physicians, today announced the commercial launch of its FDA-cleared PsiF DNA™ Sacroiliac Joint Stabilization System.
LOS GATOS, Calif., Jan. 20, 2026 /PRNewswire/ — In the pivotal clinical trial of their technology, researchers at Orlucent®, Inc. have confirmed the accuracy of the company’s Skin Fluorescent Imaging (SFI) System, a non-invasive, hand-held molecular imaging device for the direct, on-the-skin, point-of-care assessment of suspicious moles and early detection of melanoma-related activity.